Sun Pharma Warns 'New Normal' Will Push Down Its Sales Next Year
- Generic-drug pricing pressure in U.S. likely to erode revenue
- FDA sanction on key factory hampering drugmaker’s pipeline
Trump vs. Big Pharma: Can He Bring Drug Prices Down?
This article is for subscribers only.
Sun Pharmaceutical Industries Ltd., India’s largest drugmaker, warned investors that sales could decline in the coming year amid downward pressure on generic-drug prices in the U.S. and regulatory issues at one of its biggest factories.
Revenue fell 6.6 percent to 71.4 billion rupees ($1.11 billion) in the three months ended March 31 from the same period a year earlier.